KHRC CONDUCTS TRAINING FOR STAFF OF EPI-MAL-003 ON PHARMACOVIGILANCE AND DISEASE SURVEILLANCE

November 27, 2023 | News | Reading time: 2 min

The KHRC, sponsored by GlaxoSmithKline Biologicals, is conducting a study to assess the safety, efficacy, and impact of the RTS,S/AS01E vaccine (the first vaccine to be implemented for the prevention of malaria) in young children in sub-Saharan Africa.

As an integral part of this study, both medical and non-medical staff underwent comprehensive refresher training on pharmacovigilance and disease surveillance. The training sessions were held at the Seth Owusu-Agyei laboratory from November 20 to November 27, 2023.

During the training, participants were educated on the origins of pharmacovigilance, focusing on recognizing adverse events of special interest. Additionally, key aspects such as the purpose of disease surveillance, the role of pharmacovigilance in ensuring vaccine and medication safety, and the staff's role within the pharmacovigilance cycle were introduced.

Dr. George Okoth facilitated the training sessions. The training is organized every 6 months.